Ornithine

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

Retrieved on: 
Tuesday, March 19, 2024
Ornithine, Brain, PTC Therapeutics, Partnership, Deficiency, Patient, Death, Life, Therapy, Spine, PTC, FDA, AADC, BLA, Food, Pharmaceutical industry

If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.

Key Points: 
  • If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.
  • “AADC Deficiency is a devastating rare pediatric movement disorder that causes significant developmental delays and autonomic symptoms starting from birth.
  • Patients with AADC deficiency are at a high risk of death in the first decade of life,” stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro.
  • Through our partnership with PTC, we are demonstrating our commitment to drive progress for the AADC Deficiency community.”

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023

Retrieved on: 
Tuesday, May 9, 2023
Lymphoma, Amgen, Executive, Partnership, Drug development, Phenylalanine hydroxylase, Gene, CD19, Kite Pharma, Takeda, Lymphoid leukemia, CD20, Ornithine, PAH, Epithelium, Transposase, ESMO, Roche, Cancer, Breast, Oncology, Biomarker, Cell, AAV, American Society of Gene and Cell Therapy, PKU, Phenylalanine, Research and development, CAR, Development, Retirement, Genetic disorder, Novartis, Patient, Investment, SAN, Haemophilia, OTC, Mouse, Rare, European Society for Medical Oncology, Therapy, IND, News, Society, Pharmaceutical industry, Vaccine, Cryptocurrency, Research, Phenylketonuria

SAN DIEGO, May 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.  

Key Points: 
  • SAN DIEGO, May 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.
  • The Company currently expects to present further clinical updates for the program at a medical meeting in 2023.
  • The Company currently expects to present further clinical updates for the program at a medical meeting in 2023, subject to clearance with Roche.
  • Net loss was $38.8 million for the first quarter ended March 31, 2023, compared to $58.1 million for the same period of 2022.

CHOP-led Study Shows that Antibiotic-Resistant Microbes in the Gut Make C. difficile More Infectious

Retrieved on: 
Wednesday, November 16, 2022
Health, Doctor of Philosophy, University of Minnesota Medical School, Philadelphia, Hospital, Clostridioides difficile infection, RNA, IBD, Infection, VRE, Prussia, University of Virginia, Environment, Collection, Metabolomics, Clostridioides difficile (bacteria), University, Vancomycin-resistant Enterococcus, Vanderbilt University School of Medicine, Assistant, Ornithine, Pathology, Research, Association, Organic acid, Patient, Nutrient, Inflammatory bowel disease, University of Florida, University of Pittsburgh, Children's Hospital of Philadelphia, DOI, Medical laboratory, Virulence, Arginine, Gastrointestinal tract, CHOP, Public health, Dietary supplement, Pharmaceutical industry, Nature, Child, Enterococcus

PHILADELPHIA, Nov. 16, 2022 /PRNewswire/ -- Clostridioides difficile, often referred to as C. difficile or C. diff, is a bacterium that causes severe intestinal illness and, as its name suggests, can be difficult to study and treat. Approximately 1 in 6 patients infected with C. difficile will be reinfected within two months. Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others. The human gut is filled with trillions of microbes, and these microbes influence the virulence of various pathogens, but until now, scientists had little understanding of how C. difficile cooperates with the rich collection of microorganisms in the gastrointestinal tract.

Key Points: 
  • Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others.
  • Prior studies have shown that adults infected with C. difficile also have high levels of Enterococcus in their gut and that vancomycin-resistant Enterococcus (VRE) frequently co-infects patients with C. difficile.
  • They also observed a positive correlation between C. difficile burdens and ornithine, supporting a key role for this amino acid in C. difficile infection.
  • difficile."

Arizona IV Medics Announce Myers’ Cocktail As Their Best Selling IV Treatment The Past 6 Months

Retrieved on: 
Monday, October 3, 2022
Dehydration, Injection, Allergy, Flagstaff, Magnesium, Water, Folate, Glutamine, NAC, Immunity, Thiamine, B vitamins, Lysine, Electrolyte, Headache, Glutathione, Common, Ornithine, Cocktail, Fatigue, Antioxidant, Dex, Immune system, Zinc, Cell, Citrulline, Benadryl, Nutrient, Vitamin, Patient, Mineral, Vitamin C, Nursing, Tissue, Kidney, IV, Nausea, Taurine, GLOBE, Medical device, Dietary supplement, Migraine, Phoenix

Arizona IV Medics that are located at https://www.google.com/maps?ll=33.615878,-112.333003&z=7&t=m&hl=en&gl=US... and offer their mobile IV services in a 30 mile radius around the Phoenix, Tucson, Scottsdale, and Flagstaff areas.

Key Points: 
  • Arizona IV Medics that are located at https://www.google.com/maps?ll=33.615878,-112.333003&z=7&t=m&hl=en&gl=US... and offer their mobile IV services in a 30 mile radius around the Phoenix, Tucson, Scottsdale, and Flagstaff areas.
  • The nurses and paramedics at Arizona IV Medics provide supervised IV therapy with over 20 different vitamin ingredients, infusions, and injections, such as:
    Myers Cocktail Whether youre hungover, sick, or dehydrated, the Myers Cocktail is a popular choice for those searching for symptom relief.
  • The Arizona Exclusively offered by Arizona IV medics, this IV drip bag eliminates liver toxins, prevents kidney and liver damage, and is rich in saline, glutathione, and NAC.
  • To find out more about Arizona IV Medics and their popular Myers Cocktail or to read about their other IV packages, please visit their website at https://www.azivmedics.com/ .

New Review in CMJ Highlights Role of Arginine Metabolism in Pancreatic Cancer and its Treatment

Retrieved on: 
Wednesday, September 15, 2021
Drug resistance, Immunotherapy, Antibody, Metabolism, Protein, Ornithine, Malignancy, Metastasis, Autophagy, Cancer, Chinese Medical Journal, Growth, Arginine, Review, Cell death, PDAC, Pancreatic cancer, News, Dietary supplement, Pharmaceutical industry

The research group has collated studies on the role of arginine metabolism in pancreatic cancer and potential therapeutic approaches in a comprehensive review.

Key Points: 
  • The research group has collated studies on the role of arginine metabolism in pancreatic cancer and potential therapeutic approaches in a comprehensive review.
  • Dr. Lei You, the corresponding author of the article, says, "In this review, we introduce arginine metabolism and its impacts on pancreatic ductal adenocarcinoma cells.
  • Also, we discuss the role of arginine metabolism in arginine deprivation therapy and immunotherapy for cancer."
  • The review focusses on pancreatic ductal adenocarcinoma (PDAC), an extremely malignant form of pancreatic cancer with a low survival rate.

Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Wednesday, July 28, 2021
Infectious diseases, Pharmaceutical, Health, Clinical trials, Urea cycle, Branches of biology, Ornithine transcarbamylase deficiency, Ornithine transcarbamylase, ARCT, Ornithine, Arcturus Therapeutics, OTC

The ARCT-810 Phase 2 study is a randomized, double-blind, placebo-controlled, nested single and multiple ascending dose design for adolescents and adults with OTC deficiency.

Key Points: 
  • The ARCT-810 Phase 2 study is a randomized, double-blind, placebo-controlled, nested single and multiple ascending dose design for adolescents and adults with OTC deficiency.
  • We are pleased to initiate this multiple dose Phase 2 clinical trial of ARCT-810 in OTC deficiency patients.
  • Advancement to a Phase 2 study is supported by the safety results from our ARCT-810 Phase 1 trial in Healthy Volunteers, said Steve Hughes, M.D., Chief Medical Officer of Arcturus.
  • Ornithine Transcarbamylase (OTC) deficiency is a serious urea cycle disorder with a prevalence of approximately 10,000 people worldwide.

Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Monday, December 7, 2020
Research, Infectious diseases, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Urea cycle, Branches of biology, Rare diseases, Genetic genealogy, Medical genetics, Ornithine transcarbamylase deficiency, Nitrogen cycle, Ornithine transcarbamylase, Ornithine, Arcturus Therapeutics

The ongoing Phase 1b study will evaluate approximately twelve patients with OTC deficiency.

Key Points: 
  • The ongoing Phase 1b study will evaluate approximately twelve patients with OTC deficiency.
  • Arcturus previously announced that it had completed the ARCT-810 Phase 1, dose escalation study in healthy subjects, at doses up to 0.4 mg/kg.
  • We are pleased to have now initiated dosing of ARCT-810 in patients with OTC deficiency.
  • Ornithine Transcarbamylase (OTC) deficiency is a serious urea cycle disorder with a prevalence of approximately 10,000 worldwide.

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Friday, June 5, 2020
Urea cycle, Metabolism, Branches of biology, Ornithine transcarbamylase deficiency, Ornithine transcarbamylase, Ornithine, OTC, Urea, Arcturus Therapeutics

We are excited to advance ARCT-810, a highly promising mRNA-based therapeutic candidate for OTC deficiency, into a Phase 1 study.

Key Points: 
  • We are excited to advance ARCT-810, a highly promising mRNA-based therapeutic candidate for OTC deficiency, into a Phase 1 study.
  • This important milestone marks Arcturus transition into a clinical stage biopharmaceutical company, said Steve Hughes, M.D., Chief Development Officer of Arcturus.
  • The ARCT-810 Phase 1 study is a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers.
  • Ornithine Transcarbamylase (OTC) deficiency is a serious, urea cycle disorder with a prevalence of approximately 10,000 worldwide.

Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

Retrieved on: 
Monday, April 13, 2020
Branches of biology, Metabolism, Biochemistry, Arcturus Therapeutics, Ornithine transcarbamylase deficiency, Ornithine transcarbamylase, Ornithine, OTC, Urea cycle, Messenger RNA

ARCT-810, Arcturus first development candidate, represents a novel approach to treat ornithine transcarbamylase deficiency.ARCT-810 is based on Arcturus mRNA design construct and proprietary manufacturing process.

Key Points: 
  • ARCT-810, Arcturus first development candidate, represents a novel approach to treat ornithine transcarbamylase deficiency.ARCT-810 is based on Arcturus mRNA design construct and proprietary manufacturing process.
  • ARCT-810 also utilizes Arcturus extensive and propriety lipid library and employs the Company's LUNAR delivery platform to deliver OTC mRNA to hepatocytes.
  • ARCT-810 is an investigational mRNA medicine designed to enable OTC-deficient patients to naturally produce healthy functional OTC enzyme in their own liver cells.
  • Ornithine transcarbamylase (OTC) deficiency is the most common urea cycle disorder.

L-Ornithine Monohydrochloride (CAS 3184-13-2) Markets 2019 - Market Trends and Prospects, Major Players, and Main Downstream Sectors

Retrieved on: 
Thursday, May 23, 2019
Diamines, Ornithine, Urea cycle, Orn, Market research, Chemistry

DUBLIN, May 23, 2019 /PRNewswire/ -- The "L-Ornithine monohydrochloride (CAS 3184-13-2) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 23, 2019 /PRNewswire/ -- The "L-Ornithine monohydrochloride (CAS 3184-13-2) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This Global Report 2019 is a result of industry experts' diligent work on Researching the world market of L-Ornithine monohydrochloride.
  • The report helps to build up a clear view of the market (trends and prospects), identify major players in the industry, and estimate main downstream sectors.
  • The forth chapter deals with L-Ornithine monohydrochloride market trends review, distinguish L-Ornithine monohydrochloride manufacturers and suppliers.